The value of systematic lymphadenectomy during debulking ...
Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.
-
Upload
mercy-nancy-roberts -
Category
Documents
-
view
215 -
download
0
Transcript of Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.
![Page 1: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/1.jpg)
Endometrial CancerEndometrial Cancer
Surgical StagingSurgical Staging
(Role(Role of Lymphadenectomy) of Lymphadenectomy)
Karl Podratz MD PhD FACSKarl Podratz MD PhD FACS
![Page 2: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/2.jpg)
Endometrial CancerEndometrial Cancer
Surgical StagingSurgical Staging
Basis for Definitive StagingBasis for Definitive StagingExtent of DiseaseExtent of Disease
Adjuvant Rx determinantAdjuvant Rx determinant
PrognosticationPrognostication
Comparative evaluationComparative evaluation
Potentially therapeuticPotentially therapeutic
![Page 3: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/3.jpg)
Endometrial CancerEndometrial Cancer
Surgical StagingSurgical Staging
Definitive StagingDefinitive Staging
TAH/BSO/Peritoneal cytologyTAH/BSO/Peritoneal cytology
Pelvic/Paraaortic LND*Pelvic/Paraaortic LND*
Biopsy/OmentectomyBiopsy/Omentectomy
CytoreductionCytoreduction (Rx) (Rx)
*LND = Lymph node dissection
![Page 4: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/4.jpg)
Endometrial CancerEndometrial Cancer
Surgical StagingSurgical Staging
Definitive StagingDefinitive Staging
TAH/BSO/Peritoneal cytologyTAH/BSO/Peritoneal cytology
Pelvic/Paraaortic LND*Pelvic/Paraaortic LND*Biopsy/OmentectomyBiopsy/Omentectomy
CytoreductionCytoreduction (Rx) (Rx)
*LND = Lymph node dissection
![Page 5: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/5.jpg)
Endometrial CancerEndometrial CancerRole of Lymphadenectomy vs RadiotherapyRole of Lymphadenectomy vs Radiotherapy
Modality-based therapy*Modality-based therapy*
Lymphadenectomy Lymphadenectomy
RadiotherapyRadiotherapy
*Traditions, physician preferences, *Traditions, physician preferences, suboptimal study designs, etc.suboptimal study designs, etc.
![Page 6: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/6.jpg)
Endometrial CancerEndometrial CancerAnnual Incidence Cases and DeathsAnnual Incidence Cases and Deaths
ACS Estimates*ACS Estimates*
Year Cases DeathsYear Cases Deaths
1987 35,000 2,9001987 35,000 2,900
2007 39,080** 7,400***2007 39,080** 7,400***
*Ca 1987; CA 2007*Ca 1987; CA 2007
**11.7% increase; ***155% increase **11.7% increase; ***155% increase
![Page 7: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/7.jpg)
Endometrial CancerEndometrial CancerRole of Radiotherapy and LymphadenectomyRole of Radiotherapy and Lymphadenectomy
Paradigm shift necessaryParadigm shift necessaryMinimize overtreatmentMinimize overtreatment
Minimize undertreatmentMinimize undertreatment
Maximize outcomesMaximize outcomes
![Page 8: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/8.jpg)
Endometrial CancerEndometrial CancerRole of Radiotherapy and LymphadenectomyRole of Radiotherapy and Lymphadenectomy
Treatment paradigm shiftTreatment paradigm shift
Minimize overtreatmentMinimize overtreatment– Identify pts not requiring LND and/or RT Identify pts not requiring LND and/or RT
Minimize undertreatmentMinimize undertreatment– Identify pts benefiting from LND and/or Identify pts benefiting from LND and/or
RTRT
Maximize outcomesMaximize outcomes
![Page 9: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/9.jpg)
Endometrioid Endometrial CancerEndometrioid Endometrial CancerRole of Radiotherapy and LymphadenectomyRole of Radiotherapy and Lymphadenectomy
Modality-based therapy Modality-based therapy Radiotherapy vs. lymphadenectomyRadiotherapy vs. lymphadenectomy
Uterine histologyUterine histology
Disease-based therapyDisease-based therapyBased on patterns of failureBased on patterns of failure
Predicted by pathologic determinantsPredicted by pathologic determinants
Selective Lymphadenectomy Selective Lymphadenectomy
Selective Radiotherapy Selective Radiotherapy
Selective ChemotherapySelective Chemotherapy
![Page 10: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/10.jpg)
Endometrial CancerEndometrial Cancer
Selective LymphadenectomySelective Lymphadenectomy(not sampling)(not sampling)
Lymph Node Dissection (LND) Lymph Node Dissection (LND)
Low risk: Not indicatedLow risk: Not indicated
All others: Systematic All others: Systematic
![Page 11: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/11.jpg)
Endometrial CancerEndometrial Cancer
Selective LymphadenectomySelective Lymphadenectomy
Lymphadenectomy not indicated*Lymphadenectomy not indicated*
Low risk:Low risk:EndometrioidEndometrioid
G 1&2G 1&2
MI MI << 50% 50%
PTD PTD << 2 cm 2 cm
*Mariani et al. Am J Ob Gyn 2000
![Page 12: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/12.jpg)
Endometrioid Endometrial CancerEndometrioid Endometrial Cancer
Grade 1 & 2 and MI Grade 1 & 2 and MI << 50% 50%
Failures according to PTD*Failures according to PTD* Sites (DOD)Sites (DOD)
PTD Pt Failures Loc +PTD Pt Failures Loc +
(cm) (no.) no. % Loc Dist Dist(cm) (no.) no. % Loc Dist Dist
<< 2 123 3 2 3 (0) -- -- 2 123 3 2 3 (0) -- --
> 2 169 14 8 3 (1) 6 (6) 5 (4)> 2 169 14 8 3 (1) 6 (6) 5 (4)
*Primary Tumor Diameter*Primary Tumor Diameter
![Page 13: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/13.jpg)
Endometrioid Endometrial CancerEndometrioid Endometrial Cancer
Low risk:Low risk: G1/2, G1/2, << 2 cm, 2 cm, << 50% MI 50% MI
Pt % 5 yrPt % 5 yr
Treatment^ (no.) SurvivalTreatment^ (no.) Survival
Hysterectomy only 59 100Hysterectomy only 59 100
Hyst + LND* +/or RT** 64 100Hyst + LND* +/or RT** 64 100
Total 123Total 123
^3/113 recurred (vagina) without RT; all salvaged^3/113 recurred (vagina) without RT; all salvaged
*All nodes negative;*All nodes negative; **10 RT; 7 for PPC**10 RT; 7 for PPCMariani et al. Am J Ob Gyn 2000
![Page 14: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/14.jpg)
Endometrioid Endometrial CancerEndometrioid Endometrial Cancer
Low Risk: G 1/2, MI Low Risk: G 1/2, MI << 50%, 50%, PTD PTD << 2 cm 2 cm
Lymphadenectomy not indicatedLymphadenectomy not indicated
20% Over all population*20% Over all population*
29%29% Endometrioid patients* Endometrioid patients*
*Mariani et al. Am J Ob Gyn 2000
![Page 15: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/15.jpg)
Endometrioid Endometrial CancerEndometrioid Endometrial Cancer
Selective LymphadenectomySelective Lymphadenectomy
Lymphadenectomy not indicated (29%)Lymphadenectomy not indicated (29%)
Low risk:Low risk: G 1/2, MI G 1/2, MI << 50%, PTD 50%, PTD << 2 cm 2 cm
Systematic Lymphadenectomy (71%)Systematic Lymphadenectomy (71%)
All others (not low risk)All others (not low risk)
![Page 16: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/16.jpg)
Endometrioid Endometrial CancerEndometrioid Endometrial Cancer
Selective LymphadenectomySelective Lymphadenectomy
Lymphadenectomy not indicatedLymphadenectomy not indicated
Low risk:Low risk: G 1/2, MI G 1/2, MI << 50%, PTD 50%, PTD << 2 cm 2 cm
Systematic LymphadenectomySystematic Lymphadenectomy
All others (not low risk)All others (not low risk)
17%17% positive nodes positive nodes
![Page 17: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/17.jpg)
Endometrial Cancer FailuresEndometrial Cancer Failures
Pelvic Lymphatic FailuresPelvic Lymphatic Failures
Lymphatic failures according to risk factorsLymphatic failures according to risk factorsLymphatic Failure rate PLymphatic Failure rate P
Site % at 5 years ValueSite % at 5 years Value
Pelvic SidewallPelvic Sidewall
Low riskLow risk <1 <0.001<1 <0.001
High risk* 26High risk* 26
Low risk = absence of high risk factorsLow risk = absence of high risk factors
High risk = High risk = *CSI and/or LN mets*CSI and/or LN mets
![Page 18: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/18.jpg)
Endometrial Cancer FailuresEndometrial Cancer FailuresLymphatic FailuresLymphatic Failures
Lymphatic failures according to risk factorsLymphatic failures according to risk factorsLymphatic Failure rate PLymphatic Failure rate P
Site(s) % at 5 years ValueSite(s) % at 5 years Value
Pelvic SidewallPelvic Sidewall
Low risk <1 <0.001Low risk <1 <0.001
High risk* 26High risk* 26
Para-aortic areaPara-aortic area
Low risk 1 <0.001Low risk 1 <0.001
High risk** 33High risk** 33
Low risk = absence of high risk factorsLow risk = absence of high risk factors
High risk = *CSI and/or LN mets; High risk = *CSI and/or LN mets; **LN mets only**LN mets only
![Page 19: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/19.jpg)
Endometrial Cancer FailuresEndometrial Cancer Failures
Paraaortic Lymphatic InvolvementParaaortic Lymphatic Involvement
33%33% para-aortic failures with para-aortic failures with pelvic and/or para- pelvic and/or para-
aortic LN aortic LN mets mets
47%47% para-aortic LN mets or para-aortic LN mets or para-aortic failures para-aortic failures
with with pelvic LN mets* pelvic LN mets*
*Mariani et al 2002 (Mayo series)
![Page 20: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/20.jpg)
Endometrioid Endometrial CancerEndometrioid Endometrial CancerRole of Radiotherapy and LymphadenectomyRole of Radiotherapy and Lymphadenectomy
Disease-based therapyDisease-based therapyBased on patterns of failureBased on patterns of failure
Predicted by pathologic determinantsPredicted by pathologic determinants
Selective Lymphadenectomy Selective Lymphadenectomy
Selective RadiotherapySelective Radiotherapy
12% total population at risk12% total population at risk
EBRT indicated in 12%EBRT indicated in 12%
47% paraaortic risk47% paraaortic risk
RT field to include PA areaRT field to include PA area
![Page 21: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/21.jpg)
Endometrial Cancer Endometrial Cancer
Therapy after LymphadenctomyTherapy after Lymphadenctomy Conclusions:Conclusions: Absent CSI or pelvic LN mets:Absent CSI or pelvic LN mets:
adjuvant Rx to pelvic or para-aorticadjuvant Rx to pelvic or para-aorticnode-bearing areas does not appear node-bearing areas does not appear
indicated indicated
Positive (or at-risk* for) pelvic LN mets:Positive (or at-risk* for) pelvic LN mets: adjuvant Rx to both the pelvic and adjuvant Rx to both the pelvic and
para-aortic nodal areaspara-aortic nodal areas indicatedindicated *Patients at-risk but incompletely staged *Patients at-risk but incompletely staged
![Page 22: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/22.jpg)
Endometrioid Endometrial CancerEndometrioid Endometrial CancerRole of Radiotherapy and LymphadenectomyRole of Radiotherapy and Lymphadenectomy
Treatment paradigm shiftTreatment paradigm shift
Minimize overtreatmentMinimize overtreatment– Identify pts not requiring LND and/or RT Identify pts not requiring LND and/or RT
Minimize undertreatmentMinimize undertreatment– Identify pts benefiting from LND and/or Identify pts benefiting from LND and/or
RTRT
Maximize outcomesMaximize outcomes
![Page 23: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/23.jpg)
Endometrioid Endometrial CancerEndometrioid Endometrial CancerRole of Radiotherapy and LymphadenectomyRole of Radiotherapy and Lymphadenectomy
Modality-based therapy Modality-based therapy Radiotherapy vs. lymphadenectomyRadiotherapy vs. lymphadenectomy
Uterine histologyUterine histology
Disease-based therapyDisease-based therapyBased on patterns of failureBased on patterns of failure
Predicted by pathologic determinantsPredicted by pathologic determinants
Selective Lymphadenectomy Selective Lymphadenectomy
Selective Radiotherapy Selective Radiotherapy
Selective ChemotherapySelective Chemotherapy
![Page 24: Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.](https://reader033.fdocuments.net/reader033/viewer/2022050714/56649ce55503460f949b2187/html5/thumbnails/24.jpg)